instruction:
Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
question:
Paragraph: "The story does not discuss the costs of annual mammography screening, or even provide a range of costs. The story does not discuss any health care policy cost repercussions of breast cancer screening recommendations. The story does not discuss the cost of unnecessary biopsies or other treatments for women who have a false positive diagnosis via mammography (greater in women 40-49). The story highlights the 26 percent difference in breast cancer death rates, but fails to include any information about the overall risk. The researchers reported that based on their results you would have to screen 1252 women for a decade in order to prevent one breast cancer death. In other words, for the remaining 1251 women, a decade of mammograms did not alter their breast cancer mortality. Although this story does not go into detail about the potential harms of screening mammography, it does include comments from independent experts who point out that the scans do lead to the diagnosis and treatment of women whose tumors would never have become life-threatening. This story briefly explains key features of this study. It also includes critiques from independent experts who note limitations of the study design and analysis although the statement that the researchers ""did not compare the broader breast cancer death rates""in the counties"" is unclear. Overall, there is much more the Times could have done to analyze methodological questions surrounding the Swedish study. (For example, read our blog on this matter.) Interviews with Peter Gotzsche and with Donald Berry saved the story. But so much more could have been done another reason why more than 471 words should have been devoted to the reporting. The story does not discuss the prevalence of breast cancer among women in their 40s. That omission would not usually be considered disease mongering, but since surveys indicate most people overestimate the risk of breast cancer among women in their 40s, failing to mention the actual rates leaves those misconceptions intact. The story does include comments from experts who raise concerns about overdiagnosis; that is, the number of breast tumors discovered that are not actually life-threatening. A strong point of this story is the inclusion of comments from several independent experts with a variety of perspectives on the meaning of the latest study results. The story does not mention any potential conflicts of interest, but the researchers did not list any in their journal article. Although not discussed in detail, the story does mention that the United States Preventive Services Task Force has questioned the value of screening mammograms for women younger than 50, thus implying that not being screened is an option to consider. The availability of mammography was not explicitly addressed, but we can't criticize the story for that. Instead, we give a Not Applicable score for this criterion. This story could have done a better job explaining how this study and its methods are different from earlier research on the topic.But two things lead us to give it a barely satisfactory score. First, there was a brief attempt to mention the unique ""circumstances"" of the Swedish study. Second, the story also pointed out that there's a historical ideological pattern in the study authors' work noting that they ""have long been advocates of mammography screening."" It's clear that the story was not based on a news release." Claim: Mammogram Benefit Seen for Women in Their 40s
answer:
This story includes strong comments from independent experts that can help readers get a broader understanding of the results of a study that compared breast cancer death rates among women in their 40s who lived in areas of Sweden that did or did not offer routine mammography. However, because the story reports only the percentage difference in death rates, without including absolute numbers or the number of women who need to be screened to prevent one death, readers may get the impression that the effect of mammography was larger than what the researchers actually reported. People commonly overestimate the risk of breast cancer death among women in their 40s. By not including any information about the absolute numbers of deaths among women in this study or in the population at large, the story misses an opportunity to correct common misconceptions.

question:
Paragraph: "The story had a sidebar explaining the cost of Bod Pod testing in Puget Sound locations ranges from $25 50. The story indicated one might benefit from the information generated by BOD POD measurement by helping set realistic weight loss goals. It did not actually provide the reader with any information about whether evidence exists demonstrating that it is of benefit for weight loss or improvement in adiposity-related risks. The story indicated that obtaining body composition information could be anxiety or guilt provoking. Although the story stated that 'Data suggest the BOD POD is accurate', it didn't actually indicate what sort of evidence exists documenting this. While theremay beevidence that the BOD POD is ""accurate"" the story did not state whether the evidence is solid or controversial. Most importantly, the story did not address the question as to whether there is any quality evidence that knowing your body fat percentage is truly helpful in improving your health. There also wasn't any evidence presented about how effective it is to measure body fat percentage prior to engaging in a weight loss program in terms of whether it helps people lose weight. The story did not engage in overt disease mongering. In fact, it concluded that having the test is ""not a good idea if the number will be just one more thing to obsess over or feel guilty about."" Both professionals interviewed were from the private commercial sector one from a center that uses the Bod Pod (hardly an independent voice on the topic) and one who is a book author. The story would have been enhanced with the inclusion of insight from a clear expert in the field of body composition assessment. The story did a very nice job of running through the various techniques for measuring body composition and even included a link to an online calculator of body mass index (BMI). The story explained that body composition measurement with the BOD POD is hard to find because there are few locations with the apparatus. The story accurately portrayed the BOD POD as a piece of equipment that had been around for a while. We can't be sure if the story relied largely or solely on a news release." Claim: What are you made of? The BOD POD knows all
answer:
This story did a fine job of explaining the various ways body composition can be measured and what the measurement means and how it might be used. But a major shortcoming of the story was that it did not do a good job of providing a critical appraisal of the evidence behind the BOD POD device. Do we really know that it is worthwhile to measure our body fat percentage? At what cost? If it is so beneficial, why doesn't my health care provider have a BOD POD in the office? What do clinicalexperts in body composition measurement say about the evidence that the BOD POD is a more useful tool than the body mass index? All unanswered, but important, questions for this story to address. This may be a case where our star ratings are deceptively high.

question:
Paragraph: "Like its competitors, the Times did not discuss costsanomissionwhich perhaps is more acceptable in this story since it clearly indicated that this is not very close to being a marketable product. Nevertheless, we would have liked to have seen some mention of the financial impact. Many patients with type 1 diabetes are not using currently available pumps and sensors because of the high cost of these devices. It seems likely that this new treatment, if it ever becomes widely available, will be as expensive or more so than the current pump and sensor technology. We applaud the Times for avoiding the term ""artificial pancreas"" in the headline and using it sparingly in the body of the story. The competing stories couldn't resist it. We can understand whymarketers and media relations people would favor this term because of its promotional value, but we don't think it's agood way to describe this technology in an objective piece of journalism. ""Artificial pancreas"" is misleading because we're not really anywhere close tobeing able to replicate what the normal human pancreasdoes through artificial technology. Forgetting for a momentthat the pancreas does much morethan simply dispense insulin (it alsoproduces a number of other hormones anddigestive enzymes that aren't impacted by diabetes),what's more important is how the pancreas worksin concert withthe brain and other systems to regulateglucose in a very tight range. The normal human pancreas starts releasinginsulin beforewe eat in response to complex environmental cues, whereas any artificial system would need tobe told thatmeal is coming or react to therise in glucose after thefact. Plus,insulinproduced by the bodystarts acting rightaway, whereas insulin analogues take about 20 minutes to takeeffect. Put this all together and we see that the ""artificial pancreas"" will, for the foreseeable future, require human intervention to predictpost-mealinsulin needs and dosing or else patients will be at risk of post-meal blood sugar spikes. And it's not at all clear that such a systemwill improve overall bloodsugar management compared with existing methods. The term""artificial pancreas"" conjures up a vision of totally automated glucose management and essentially a ""cure"" for type 1 diabetes. This isoverselling what the technology can do. The Times waited until the last 3 paragraphs of an 1,100-word story to hintthat an automated system could deliver unsafe doses of insulin. It isn't until the last sentence thatwe learn that the system would need to be ""exquisitely reliable"" in order to be safe. We feel the story should have raised these issues earlier and that it could have done more to emphasize just how difficult itwill befor any device to calculate insulin requirements on the fly. Insulin dosingis affected byfactorsranging from how much aperson has exercised to whatand how much they have eaten. It's conceivable that technology can account for all of these variables,but there are a lot ways thingscould go wrong, with potentially deadly results. It's a close call, butwe don't feel thestorydid enough to call attention to these issues. In contrast to its competitors, which allled readersto believe there had been a fully automated system sensing glucose levels and dispensing insulin to the participants in this study, the Times noted thatthe insulin was dispensed by a nurse based oncalculations made by a computer algorithm. The Times clearly indicated that the significance of this test was as a ""proof of concept"" that the algorithm works and is safe, not as a test of any specific device. It noted that a fully automated system combining glucosemonitoring and insulin delivery was still ""hypothetical."" In addition,the Times story wasthe only one to draw attention to the small size of this study and the fact the findings were not statistically significant for the primary outcomes. This noteofcaution was completely lacking from the competingcoverage. The story did not exaggerate the effects of type 1 diabetes. The story includes quotesfrom interviews with one of the study investigators and another researcher, and identifies both as having ties to diabetes products manufacturers. It also quotes an analyst at an investment firm. It would have been better had theyincluded one more source who didn't have commercial ties to specific products. The story describes currently available technology for glucose monitoring and insulin infusion. It describes the limitations of current approaches for managing insulin, especially during the overnight period. The story is a bit misleading in that it leaves the impression that all type 1 diabetics are currently using pumps at night. This is not actually the case. Most people are doing self monitoring of blood glucose and making judgement calls on whether and how much insulin to administer. However, the story does enough for a satisfactory in our view. The Times did a good job of describing the system used in this study and how close it is to being commercially available. It called the system ""experimental""and said that it was ""notfully automated."" It said that a fullyautomated glucose monitor/insulindelivery system was still ""hypothetical"" and would face regulatory hurdles before it could be marketed to the public. The story describes the progression from skin prick glucose testing to continuous monitoring and insulin pumps. It places the new developments in this field on this continuum. There could have beenmore discussion of many of the recent advances that have made daytime hyper- and hypoglycemia less of a problem such asthe newer short-acting insulins. The story did not rely on any news release." Claim: Insulin Study Could Lead to New Dosage Devices
answer:
With its balanced coverage of an experimental system for managing blood glucose in type 1 diabetes, the Times demonstrates why it isoften a cut above most other health media outlets. Of the three competing storieswe lookedat, the Times' was the onlyone to avoid thehyped-upterm "artificial pancreas" in its headline. It's also the only story to accurately portray what actuallyhappened in this experiment; the only one to identify conflicts of interest; andthe only one tooffer any kind ofskeptical perspectivefroman independent observer. The study covered here represents a potentially important advance on the road to an automated system for managing blood sugar in patients with type 1 diabetes. By laying out the potential of such a system in sober terms and pointing out the many obstacles that still lay in its path to development and approval, the Times conveys the significance of the findings but doesn't provide false hope.